International Symposia on Recent Advances in Otitis Media

项目摘要 目前正在请求为三次中耳炎最新进展国际专题讨论会提供部分支助。的 中耳炎（OM）在世界范围内的流行以及引起OM的抗生素耐药性细菌的惊人增加 使其成为严重的公共卫生问题。因此，迫切需要更好的方法来诊断，治疗， 最终预防OM。然而，要做到这一点，需要全面了解这一点的各个方面。 儿童疾病，2020年健康人（听力和其他感官或沟通）的既定目标 疾病，ENT-VSL-2：“减少儿童和青少年中耳炎”），以及NIDCD战略计划FY 2017-2021年，其中优先领域2 -了解疾病和障碍，宣布改善 我们对OM的易感性和发病机制的理解与遗传学、先前的上呼吸道感染、 肠道感染，咽鼓管功能障碍和反流，细菌生物膜和微生物组，多微生物 感染、先天免疫失调、炎症和粘液产生、粘膜增生和 炎症消退和组织修复的失调。定义有效的免疫途径 疫苗对中耳的保护，新治疗靶点的确定以及 急性和慢性OM的动物模型，确定疫苗接种对疾病流行的影响， 其他微生物感染也被列为这一优先研究领域的主要目标。的目标 中耳炎最新进展国际研讨会完全和独特地与这些 战略目标。我们坚信，科学发现的速度需要定期的广泛和深入的研究。 每两年对OM的研究进展进行一次回顾。重要的是，这是一个额外的机会， 每四年召开一次研究委员会会议，就未来的研究方向和拨款提出建议。 研讨会内的综合研究会议（发生在美国-召开的研讨会）也是 这对我们共同努力确定和促进新的和创新的研究机会具有重大价值。 因此，在NIDCD工作人员的许可和建议下，我们在此请求支持， 为期5年，在此期间，我们将召开第20届，第21届和第22届国际研讨会， 中耳炎进展（分别于二零一九年、二零二一年及二零二三年）。第20届研讨会将于6月20日召开。 9-13在加州的洛杉矶举行;第21届研讨会将于6月6日至10日在以色列的特拉维夫举行; 第22届研讨会将在美国召开，地点将在第20届研讨会上决定。这些 预计研讨会将促进OM中不同研究学科之间的交流 研究领域，并帮助缩小差距，在我们的集体知识和理解的发病机制，以及 作为OM的诊断、治疗和/或免疫学解决的潜力。本次研讨会还 不断吸引来自许多学科和世界各地的年轻研究人员，从而确保了 未来一代的基础科学和临床研究人员将继续推动该领域的发展。

PROJECT SUMMARY Partial support is being requested for three International Symposia on Recent Advances in Otitis Media. The worldwide prevalence of otitis media (OM) and alarming increase in antibiotic resistant bacteria that cause OM make this a serious public health problem. Thus, there is a pressing need for better ways to diagnose, treat and ultimately, prevent OM. To do so however requires a complete understanding of all aspects of this pediatric disease, a stated goal of both Healthy People 2020 (Hearing and Other Sensory or Communication Disorders, ENT-VSL-2: “Reduce otitis media in children and adolescents”), and the NIDCD strategic plan FY 2017-2021, wherein Priority Area 2 – Understanding Diseases and Disorders, declares a mandate to improve our understanding of the susceptibility and pathogenesis of OM as related to genetics, prior upper respiratory tract infection, Eustachian tube dysfunction and reflux, bacterial biofilms and microbiome, polymicrobial infections, dysregulation of innate immunity, inflammation and mucus production, mucosal hyperplasia and dysregulation of the resolution of inflammation and tissue repair. Defining the immune pathways for effective middle ear protection by vaccines and identification of new therapeutic targets as well as development of animal models of acute and chronic OM, determination of the impact of vaccination on disease prevalence and infection by other microbes are also cited as major goals within this priority research area. The objectives of the International Symposia on Recent Advances in Otitis Media are fully and uniquely aligned with these strategic goals. We strongly believe that the speed of scientific discovery requires regular broad and in-depth review of the research progress in OM every two years. Importantly, an additional opportunity to define and formulate recommendations for future research directions and funding every four years by the convening of an integrated Research Conference within the Symposium (occurs during U.S.-convened symposia) is also of great value to our collective efforts to identify and promote new and innovative research opportunities. Thereby, with permission and recommendation from NIDCD staff, herein we request support that will span a period of 5 years, during which we will convene the 20th , 21st and 22nd International Symposia on Recent Advances in Otitis Media (in 2019, 2021 and 2023, respectively). The 20th Symposium will be convened June 9-13 in Los Angeles, California; the 21st Symposium will be convened June 6-10 in Tel Aviv, Israel; and the 22nd Symposium will be convened at a U.S. destination that will be decided at the 20th Symposium. These Symposia are expected to foster improved communication amongst diverse research disciplines in the OM research field and help close gaps in our collective knowledge and understanding of the pathogenesis as well as the diagnosis, treatment and/or potential for immunological resolution of OM. This Symposium has also consistently attracted young investigators from many disciplines and from around the world, thus ensuring a future generation of both basic science and clinician investigators who will continue to move the field forward.